Gefitinib works by binding to the ATP-binding site of the EGFR tyrosine kinase, thereby inhibiting its activity. This inhibition prevents the downstream signaling pathways that promote cell proliferation and survival. Essentially, gefitinib interrupts the signals that tell cancer cells to grow and divide, leading to reduced tumor growth and potentially tumor shrinkage.
